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Abstract: The rising incidence of invasive fungal infections due to the expanding population 
of immunocompromised hosts and the increasing prevalence of fungal resistance has led to the 
need for novel antifungal agents. Posaconazole, a new member of the triazole class has dem-
onstrated in vitro activity against a broad spectrum of fungi and clinical activity against various 
fungal pathogens, including Aspergillus spp., Candida spp., zygomycetes, and Fusarium spp. 
To date, posaconazole has been approved for prophylaxis of invasive fungal infections in stem 
cell transplant recipients with acute graft versus host disease (GVHD) and neutropenic patients 
receiving intensive induction chemotherapy for acute myelogenous leukemia and myelodys-
plastic syndrome. In addition, it has been licensed for use in oropharyngeal candidiasis and for 
salvage therapy in invasive aspergillosis, fusariosis, coccidioidomycosis, chromoblastomycosis, 
and mycetoma. Posaconazole is the only azole with activity against zygomycetes and other 
difﬁ  cult-to-treat fungi, representing a potential treatment option for refractory invasive mycosis. 
This article reviews available preclinical and clinical data of posaconazole, focusing on its role 
in the teatment of refractory invasive fungal infections.
Keywords: posaconazole, refractory invasive fungal infections, salvage therapy
Introduction
Invasive fungal infections (IFI) have increased signiﬁ  cantly as a leading cause of 
life-threatening conditions in immunocompromised patients over the past two decades 
(Marr et al 2002; Wisplinghoff et al 2004). This is primarily due to the rise of at-risk 
individuals comprising immuncompromised patients with prolonged neutropenia or 
advanced HIV infection, and patients who have undergone allogeneic hematopoietic 
stem cell transplantation (HSCT) or solid organ transplantation. Improvement in 
anticancer treatment, greater duration and intensity of immunosuppression, and the 
variety of available antimicrobial therapies have inﬂ  uenced the spectrum of pathogens 
associated with IFI. Although Candida and Aspergillus spp. remain the principal 
causes of most IFI, mycoses due to more unusual fungal pathogens like Cryptococcus, 
Coccidioides, Histoplasma, and agents of zygomycosis (primarily species of Rhizopus, 
Mucor, Cunninghamella, Apophysomyces, Absidia, and Rhizomucor) have become 
more prevalent in recent years. In fact, the effectiveness of routine ﬂ  uconazole pro-
phylaxis has resulted in a reduction of C. albicans infections, but has also caused 
a shift to non-albicans Candida spp., ie, C. krusei and C. glabrata – representing 
ﬂ  uconazole-resistant strains – and C. parapsilosis (Pfaller et al 1998; Marr et al 2000; 
Baran et al 2001). To date only four classes of antifungal agents have been approved 
for the treatment of IFI: the azoles such as itraconazole, ketokonazole, ﬂ  uconazole, and 
voriconazole; the polyenes, the most prominent of which is amphotericin B; ﬂ  ucytosine, 
a drug inhibiting fungal RNA and DNA synthesis; and the echinocandins, such as 
caspofungin, anidulafungin, and micafungin (Table 1). Failure rates of these agents, 
including the recently introduced agents, such as voriconazole and caspofungin, are Therapeutics and Clinical Risk Management 2008:4(4) 748
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still high – up to 60%–80% in allogeneic HSCT recipients 
(Barnes and Marr 2007). Hence there is an obvious need for 
new, more potent, broad-spectrum antifungal agents.
Posaconazole (Noxaﬁ  l®; Schering-Plough), an extended-
spectrum triazole has been recently approved for prophylaxis 
and treatment of refractory IFI by the EMEA and the FDA. 
The aim of this review is to summarize the in vitro and 
clinical data available on posaconazole with special focus 
on refractory invasive mycoses.
Mode of action and mechanism
of resistance
Posaconazole is a lipophilic triazole with structural simi-
larity to itraconazole. The azole class of drugs inhibits 
the cytochrome P450 (CYP450)-dependent lanosterol 14 
alpha-demethylase (CYP51), an enzyme required for ergos-
terol production which is an essential sterol component in 
the cell membrane of fungal pathogens but is not present 
in mammalian cells (Munayyer et al 2004; Wexler et al 
2004). Exposure to posaconazole is a more potent inhibitor 
of sterol synthesis in Aspergillus fumigatus and A. ﬂ  avus 
than either itraconazole or voriconazole. Posaconazole has 
an exceptional high afﬁ  nity to CYP51. Since posaconazole 
has a chemical structure different from that of ﬂ  uconazole 
and voriconazole, it can interact with an additional domain 
of the target so that it inhibits even mutated strains resistant 
to ﬂ  uconazole and voriconazole (Munayyer et al 2004; Hof 
2006). CYP51 is encoded by the ERG11 gene in Candida 
albicans and is present in almost all yeasts and molds, with 
the exception of Pneumocystis spp. and Phytium spp. (Hof 
2006). Inhibition of CYP51 results in depletion of ergosterol 
from the fungal cell membrane and accumulation of methyl-
ated sterol precursors. This results in membrane instability, 
increased permeability, and inhibition of cell growth (Kwon 
et al 2007).
Mechanisms of resistance to azole antifungals have 
been reported to occur via both mutation of CYP51 and 
upregulation of genes controlling drug efﬂ  ux pumps (Lupetti 
et al 2002; Hof 2006). The target site for the azoles is the 
ERG11 gene product encoding the cytochrome P450 lanos-
terol 14 alpha-demethylase, an essential enzyme in the 
biosynthetic pathway of ergosterol. Many of the identiﬁ  ed 
CYP51 mutations map to the active site of the enzyme, 
thereby reducing the binding afﬁ  nity of the respective azoles 
to their cellular target. Mutations seem to preferentially affect 
binding of ﬂ  uconazole and voriconazole versus itracon-
azole and posaconazole, probably because of the long side 
chain of the latter two agents (Xiao et al 2004; Kwon and 
Mylonakis 2007). Based on 3D models of CYP51 bound to 
azoles, these side chains occupy a speciﬁ  c channel within 
CYP51, and this additional interaction serves to stabilize 
the binding of these azoles to the mutated CYP51 proteins 
(Xiao et al 2004). The model also predicts that mutations 
that were previously shown to speciﬁ  cally impact posacon-
azole susceptibility in A. fumigatus and C. albicans act by 
interfering with the binding of the long side chain. Azoles 
passively diffuse into fungal cells and resistance of yeasts 
as well as molds can develop when transmembrane efﬂ  ux 
pumps are activated, thereby decreasing the intracellular 
drug concentration. The transporters of the ABC family 
CDR1 and CDR2 together with the major facilitator efﬂ  ux 
gene MDR1 have all been implicated in the development 
of fungal resistance to azoles. However, these efﬂ  ux pumps 
seem to work less efﬁ  cient when exporting posaconazole in 
comparison to the other azoles (Chau et al 2004; Akins 2005). 
CDR1 and CDR2 have been shown to efﬁ  ciently transport 
ﬂ  uconazole, ketoconazole, itraconazole, and voriconazole, 
whereas posaconazole is transported to a much lesser degree. 
MRD1 can speciﬁ  cally transport ﬂ  uconazole but has no effect 
on posaconazole (Akins 2005).
Pharmacokinetics and metabolism
Posaconazole is available as an oral suspension administered 
at 800 mg daily in 2 or 4 daily doses for salvage treatment or 
600 mg daily in 3 daily doses for prophylaxis. The pharma-
cokinetics of posaconazole have been studied in single- and 
multiple-dose studies in healthy volunteers. Collectively, 
these studies have established that posaconazole displays 
a linear, dose-proportional pharmacokinetic up to single 
doses of 800 mg daily (Courtney et al 2003, 2004; Krieter 
et al 2004). Posaconazole is orally bioavailable, with maxi-
mum concentrations reached approximately 10 hours post 
dose. The absorption of posaconazole is linear through the 
clinically useful dose of 400 mg every 12 hours; absorption 
is saturated at higher doses and, thus, loading doses are 
not possible (Krieter et al 2004). Like itraconazole, food 
greatly affects posaconazole absorption. Absorption of the 
oral suspension increases approximately 2-fold when taken 
with food, and 4-fold with a high-fat meal (Courtney et al 
2004). Multiple-dose studies demonstrated that splitting the 
dose increased the total amount of drug absorbed (Courtney 
et al 2003). Posaconazole has a large volume of distribution 
(486 L) – compatible with good tissue penetration – and 
is 95% protein bound. It undergoes limited hepatic 
metabolism, via UDP glucuronidation and less through the 
oxidative pathways of the CYP450 system. Elimination Therapeutics and Clinical Risk Management 2008:4(4) 750
Langner et al
occurs predominantly through fecal excretion (77%) and 
to a lesser extent through urinary excretion (14%) (Ghosal 
et al 2004; Krieter et al 2004). As a result of posaconazole’s 
high protein binding and extensive distribution, the terminal 
plasma elimination half-life is approximately 20 hours, and 
steady-state concentrations are reached within approximately 
7–10 days after initiation of therapy (Krieter et al 2004). This 
might affect its use in primary therapy for IFI. In a small 
study comprising patients with varyious degrees of hepatic 
dysfunction, a trend of increasing half-life indicating pro-
longed elimination was visible; however, the area under the 
curve (AUC) did not signiﬁ  cantly change and therefore, at 
this time, no dose adjustment is suggested for patients with 
hepatic impairment (Courtney et al 2000). In a small study of 
24 patients with mild to moderate renal impairment, there was 
no correlation between pharmacokinetics of posaconazole 
and mild (creatinine clearance 50–80 mL/min) to moder-
ate (creatinine clearance 20–49 mL/min) renal dysfunction 
after a single 400 mg oral dose. The drug was not removed 
by hemodialysis. These data indicate that posaconazole can 
be administered to subjects with varyious degrees of renal 
impairment without dose adjustment, and supplemental doses 
are not needed after hemodialysis (Courtney et al 2005; 
Ramsewak et al 2005). Mucositis in neutropenic stem cell 
transplant recipients appears to reduce posaconazole absorp-
tion but did not signiﬁ  cantly affect mean total posaconazole 
exposure at steady state condition. Moreover, this reduction 
could be overcome by increasing the total dose and dosing 
frequency (Gubbins et al 2006).
Drug interactions
Drug interactions mediated by various CYP450 are com-
mon with the currently available triazole antifungals; 
however, recent results suggest that posaconazole may 
have an improved drug interaction proﬁ  le compared with 
other triazoles (Wexler et al 2004). Unlike other azoles, 
posaconazole is not a signiﬁ  cant substrate for the CYP450 
enzymes and has been shown to inhibit only CYP3A4. 
Therefore, posaconazole has the potential to interact with 
other drugs that are metabolized through the 3A4 enzyme 
system (Ramsewak et al 2005). Pharmacokinetic studies 
in special populations revealed no necessity for dosage 
adjustment based on differences in age, gender, race, or 
renal or hepatic function (Groll and Walsh 2005). The 
effect of posaconazole on the pharmacokinetics of tacro-
limus and ciclosporin was evaluated in healthy subjects 
and transplant patients revealing that clearance of these 
immuno-suppressive agents was signiﬁ  cantly decreased 
while the half-life increased. Therefore, when used in 
combination with mold-active azoles, calcineurin inhibitor 
doses should be reduced by at least 50% and their blood 
or serum concentrations should be closely monitored 
(Groll and Walsh 2005; Gubbins 2007). The clearance of 
posaconazole increased 2-fold in the presence of rifabutin, 
a potent inducer of CYP3A4. Therefore, co-administration 
of these two drugs is not advocated. Likewise, concomitant 
use of posaconazole with phenytoin or cimetidine should 
be avoided because these drugs decrease posaconazole 
concentrations by approximately 50% and 40%, respec-
tively (Torres et al 2005). No dose adjustments are needed 
when posaconazole is coadministered with drugs such as 
glipizide, zidovudine, or lamivudine (Groll and Walsh 
2005). Co-administration with CYP3A4-metabolised statins 
(simvastatin, lovastatin, atorvastatin) is contra-indicated 
as is co-administration with nonsedating antihistamines, 
cisapride, quinidine, or halofantrine, which may induce 
QT prolongation and torsades de pointes (Metcalf and 
Dockrell 2007; Zonios and Bennett 2008). Because interac-
tions caused by itraconazole have been extensively studied 
and both itraconazole and posaconazole inhibit CYP3A4, 
drugs with known interaction to itraconazole should be used 
with caution in posaconazole-treated patients (Zonios and 
Bennett 2008). Since most drug-drug interaction investiga-
tions involving posaonazole have not yet been published, 
at this time the best sources for potential interactions with 
posaconazole is the prescribing information.
In vitro studies
Aspergillus spp./activity against molds
Filamentous fungal pathogens are increasingly becoming a 
major cause of IFI in immunocompromised patients. Most of 
these infections are caused by A. fumigatus (90%), followed 
by A. ﬂ  avus, A. niger, and A. terreus (Kwon and Mylonakis 
2007). Voriconazole is generally regarded as treatment of 
choice for invasive aspergillosis (Herbrecht et al 2002; Walsh 
et al 2008). However, Pfaller evaluated the in vitro antifungal 
activities within the SENTRY Antimicrobial Surveillance 
Program in the US and Canada of the new triazole anti-
fungal agents, including posaconazole, voriconazole, and 
itraconazole, as well as amphotericin B, against 239 clinical 
isolates of ﬁ  lamentous fungi. Overall, posaconazole was 
the most active compound, inhibiting 94% of isolates at 
a minimal inhibitory concentration (MIC) of 1 μg/mL, 
followed by voriconazole (91%), amphotericin B (89%), 
ravuconazole (88%), and itraconazole (70%). Posaconazole 
also exhibited excellent activity (MICs, 0.03–1 μg/mL) Therapeutics and Clinical Risk Management 2008:4(4) 751
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against less common filamentous fungi tested such as 
A. niger, A. ﬂ  avus, A. versicolor, and A. terreus, which is 
often resistant to amphotericin B. None of the triazoles were 
active against Fusarium spp. These data have been largely 
conﬁ  rmed by a more recent report of the SENTRY study 
group (Diekema et al 2003). Also, in studies assessing the 
activity of posaconazole against approximately 19,000 clini-
cally important strains of yeasts and molds including 1,423 
Aspergillus spp., isolates collected from 200 medical centers 
worldwide over a 10-year time span, posaconazole was more 
or equally active than the comparator drugs itraconazole, 
ﬂ  uconazole, voriconazole, and amphotericin B in almost all 
molds tested. Remarkably, posaconazole was active against 
isolates of Candida and Aspergillus spp. that exhibited 
resistance to ﬂ  uconazole, voriconazole, and amphotericin B 
and was much more active than the other triazoles against 
zygomycetes (Sabatelli et al 2006). However, A. niger seems 
to be less susceptible to posaconazole (Espinel-Ingroff 2003). 
The clinical implications of raised posaconazole MICs are 
unclear since it may be possible to achieve clinical serum 
posaconazole concentrations higher than these MICs (Torres 
et al 2005).
Zygomycosis
Zygomycosis is an increasingly emerging life-threatening 
infection that particularly affects patients with diabetes 
or malignancy. Posaconazole appears to be the only azole 
that demonstrates activity against most Zygomycetes. The 
most common pathogens of human disease are Rhizopus 
spp. (47%) and Mucor spp. (18%), followed by Cunning-
hamella bertholletiae (7%) and Apophysomyces elegans 
(6%) (Roden et al 2005). Amphotericin B remains ﬁ  rst 
line therapy, but posaconazole has shown in vitro activity 
against many strains of zygomycetes (Dannaoui et al 2003; 
Sabatelli et al 2006; Sun et al 2002). A recent comparative 
study comprising 19,000 yeast and mold isolates, 86 of 
which were Zygomycetes with voriconazole and itraconazole 
showed that posaconazole exhibited the lowest MICs against 
Zygomycetes isolates (Sabatelli et al 2006). In a study of 37 
strains of Zygomycetes, posaconazole was effective against 
Mucor spp., Rhizopus spp., Absidia spp., Rhizomucor spp., 
C. bertholletiae, and A. elegans (Sun et al 2002; Kwon and 
Mylonakis 2007).
Candida spp./activity against yeasts
The incidence of invasive candidiasis is increasing and Can-
dida spp. are now the fourth most common cause of blood-
stream infection (Gudlaugsson et al 2003; Pappas 2006). 
The mortality attributable to invasive candidiasis ranges 
from 30% to 71% with signiﬁ  cant variation between dif-
ferent Candida spp. (ie, in hematologic malignancies the 
mortality is highest for C. albicans and C. tropicalis and 
lowest for C. parapsilosis), as well as underlying condi-
tions, comorbidity and therapeutic procedure (for example 
HSCT, corticosteroid therapy, antibiotics) (Pagano et al 
2006; Staber et al 2007). C. albicans is the most common 
cause of candidemia in adults and children, and is respon-
sible for 40%–77% of cases (Pappas et al 2006). The in 
vitro activity of posaconazole has been tested against over 
10,000 clinical Candida isolates (Pfaller et al 2004; Cuenca-
Estrella et al 2006; Sabatelli et al 2006). In vitro, posacon-
azole is highly active against Candida spp. The drug is 
more active than itraconazole and ﬂ  uconazole against all 
Candida spp. and Cryptococcus neoformans. During the 
ARTEMIS global antifungal surveillance program, 4,169 
clinical isolates of Candida spp. were investigated for in 
vitro susceptibilities of voriconazole, posaconazole, and 
ﬂ  uconazole (Pfaller et al 2004). Both voriconazole and 
posaconazole were more active than ﬂ  uconazole against 
all Candida spp. and C. neoformans. Posaconazole was the 
most active azole tested, and was unaffected by ﬂ  uconazole 
resistance in C. albicans isolates and also had activity 
against Candida spp. that are commonly azole resistant, 
including C. glabrata and C. krusei. Posaconazole exhibited 
fungistatic and fungicidal activity in vitro and in vivo for 
most Candida spp. isolates and inhibited 97% of Candida 
spp. isolates at concentrations of 1 μg/mL or below (Pfaller 
et al 2001; Espinel-Ingroff 2003). C. albicans is the most 
susceptible species of Candida whereas C. glabrata and 
C. pelliculosa are the least susceptible (Pfaller et al 2001, 
2004; Carrillo-Munoz et al 2005). Nevertheless, posacon-
azole showed good activity against ﬂ  uconazole resistant 
strains especially Candida glabrata, although it was slightly 
less active than voriconazole (Sabatelli et al 2006; Pfaller 
et al 2008).
Cryptococcus neoformans
Cryptococcosis is one of the leading community-acquired 
opportunistic mycoses and serious disease (eg, meningitis and 
cryptococcemia) predominantly occurs in immunocompro-
mised hosts with organ transplantation, hematologic malig-
nancies, or advanced HIV, particularly those not receiving 
highly active antiretroviral therapy (HAART). Posaconazole 
has shown good in vitro activity against C. neoformans iso-
lates and also inhibited ﬂ  uconazole-resistant C. neoformans. 
A study of 1,811 global clinical isolates of C. neoformans Therapeutics and Clinical Risk Management 2008:4(4) 752
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showed that of the 1,646 that were tested against posacon-
azole, 99% had MIC 1 μg/mL (Pfaller et al 2005).
Clinical studies
Role of posaconazole as salvage therapy for invasive fungal 
infections
Salvage therapy of IFI generally refers to the treatment of 
individuals who are refractory or intolerant to initial therapy, 
administered for at least 1 week. Besides various case reports 
several clinical trials of salvage therapy have been under-
taken, but most were noncomparator studies or contained a 
nonrandomized control group. Furthermore response criteria 
used to document refractory disease differed between these 
studies. Of note, salvage therapy trials frequently include 
patients both refractory and intolerant to standard therapy, 
but patients enrolled because of intolerance have a much 
better response rate (Maertens et al 2004). When evaluating 
the results from existing salvage studies one has to take these 
limitations into consideration.
Invasive aspergillosis
Mortality rates associated with invasive aspergillosis (IA) 
are still extremely high, particularly in patients undergoing 
allogeneic HSCT (mortality rate exceeding 50%) and in 
patients with central nervous system or disseminated infec-
tion (Lin et al 2001; Upton et al 2007). A. fumigatus remains 
the leading cause for these infections, followed by A. ﬂ  avus, 
A. niger, and A. terreus, a species that is often resistant to 
antifungal therapy including amphotericin B. At present, 
voriconazole is recommended as the primary treatment of 
IA in most patients (Herbrecht et al 2002; Walsh et al 2008). 
To date only two clinical externally controlled, open label, 
multi-center trials have investigated posaconazole as salvage 
therapy in refractory IA. In the ﬁ  rst, 107 patients (initially 
receiving amphotericin B in most cases) refractory (88%) or 
intolerant (12%) to conventional therapy were treated with 
posaconazole (800 mg daily in divided doses) for a median 
duration of 52 days. Selected subjects of the control group 
received the best available standard of care for salvage 
therapy. The overall success rate (deﬁ  ned as complete or 
partial response) was 42% for posaconzole recipients and 
26% for control subjects (Walsh et al 2007). The second 
study compared 53 patients with hematologic malignan-
cies receiving posaconazole salvage therapy (800 mg daily, 
median duration 70 days) with 52 contemporary controls 
treated with high-dose lipid formulation of amphotericin 
B (HD-LPD/AMB at 7.5 mg/kg daily) and with 38 other 
control patients receiving caspofungin and HD-LPD/AMB. 
The overall rate of response to posaonazole was 40%, 
compared with only 8% and 11% for HD-LPD/AMB alone 
or in combination with caspofungin, respectively. After a 
follow-up of 12 weeks the overall survival was signiﬁ  cantly 
improved in the posaconazole arm (Raad et al 2008).
In conclusion, these studies indicate that posaconazole 
is an effective option for salvage therapy for invasive 
aspergillosis predominantly in patients with hematologic 
malignancies. Nevertheless, randomized clinical trials to 
deﬁ  ne further the role of posaconazole in IA are warranted, 
including patients with refractory aspergillosis after ﬁ  rst-line 
therapy with voriconazole.
Oropharyngeal candidiasis in patients 
with HIV
In patients with HIV and AIDS, oropharyngeal and esopha-
geal candidiasis is the most prevalent opportunistic infection. 
Fluconazole and itraconazole treatment is usually effective 
whereas refractory disease can be observed in 5% of HIV 
patients, especially in those with advanced HIV infection 
who have received multiple courses of azole antifungals 
(Fichtenbaum and Powderly 1998). In the only multi-center, 
randomized, evaluator-blinded trial of 350 HIV patients with 
oropharyngeal candidiasis, posaconazole showed noninferior-
ity to ﬂ  uconazole and a trend to prolonged clinical success after 
treatment was stopped. Both drugs were administered 14 days 
(dosed at 200 mg on day one followed by 100 mg daily) and 
clinical success (evaluated as cure or improvement) was seen 
in 92% in the posaconazole versus 95% in the ﬂ  uconazole arm 
(Vazquez et al 2006). Addressing the role of posaconazole in 
azole-refractory oropharyngeal and esophageal candidiasis, 
to date two noncomparative, open-label, multicenter studies 
demonstrated clinical response rates from 73% to 88%, long-
term safety, and good tolerability. Posaconazole was admin-
istered 400 mg twice daily, in the ﬁ  rst trial (Skiest et al 2007) 
for a treatment period of 28 days, and up to 12 months in the 
second trial (Vazquez et al 2007), demonstrating long-term 
safety, and good tolerability and efﬁ  cacy.
In summary, posaconazole offers a new, safe, and effec-
tive oral treatment option for patients with HIV and azole-
refractory mucosal candidiasis.
Zygomycosis
Zygomycosis is a group of frequently lethal mold infections 
that usually affects diabetic patients and steroid-treated or 
severely immunocompromised individuals. Most human 
infections are caused primarily by species of Rhizopus, 
Mucor, Cunninghamella, Apophysomyces, Absidia, and Therapeutics and Clinical Risk Management 2008:4(4) 753
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Rhizomucor. Zygomycetes are highly angioinvasive 
infections rapidly invading tissue and blood vessels, thereby 
leading to tissue destruction, thrombosis, infarction, and 
dissemination. Historically, the agent of choice was con-
ventional amphotericin B at relatively high doses up to 1.5 
mg/kg daily, which has largely been replaced by less toxic 
lipid formulations (Walsh et al 1998; Gleissner et al 2004). 
Two non-comparative, non-randomized open-label studies of 
posaconazole for salvage therapy of zygomycosis are avail-
able. One report analyzed data from 24 subjects refractory 
or intolerant to predominantly liposomal amphotericin B as 
ﬁ  rst-line therapy. Median time of posaconazole (800 mg daily 
in divided doses) administration was 182 days. Complete 
response, deﬁ  ned as resolution of signs of infection and no 
relapse within 30 days after cessation of medication, was 
observed in 46%, and partial response occurred in 33%. 
Five treatment failures occurred, deﬁ  ned as the presence 
of zygomycosis at the time of termination of posaconazole 
treatment or at death. Eighteen patients underwent surgical 
debridement resulting in a signiﬁ  cant better survival (Green-
berg et al 2006). In a second study, posaconazole (800 mg 
daily in divided doses) was evaluated for salvage therapy 
in 91 cases of probable or proven zygomycosis infection. 
Pretreatment consisted of amphotericin B in most patients. 
81 subjects have failed conventional therapy and 10 showed 
intolerance or both. Overall, at 12 weeks, 60% of patients 
had either a complete or partial response to treatment, 17% 
demonstrated treatment failure, and the remainder had 
stable disease. Success rates were similar irrespective of 
site of infection or whether surgical debridement had been 
performed (van Burik et al 2006).
In refractory zygomycosis, posaconazole constitutes 
a suitable oral treatment option although to determine its 
place as ﬁ  rst-line therapy a prospective randomized com-
parison of posaconazole and lipid amphotericin B needs to 
be performed.
Other invasive fungal infections
Cryptococcal meningitis/fungal CNS infections
Morbidity and mortality associated with fungal infections of 
the CNS remains unacceptably high despite treatment with 
a broad variety of antifungal agents. C. neoformans is the 
most common fungal agent in patients infected with HIV. 
Existing treatment guidelines for cryptococcal meningitis 
recommend therapy with amphotericin B with or without 
ﬂ  ucytosine (Saag et al 2000); however, clinical response 
rates in HIV-infected individuals are low. In a multi-center, 
open-label clinical trial, 39 mostly HIV-positive patients with 
fungal infection of the CNS (29 of them had cryptococcal 
meningitis) refractory or intolerant to standard therapy 
with amphotericin B or ﬂ  uconazole received posaconazole 
800 mg daily for a mean duration of 81 days. Successful 
outcomes were observed in 14 of 29 (48%) subjects with 
cryptococcal meningitis and in 5 of 10 (50%) patients with 
CNS infections due to other fungal pathogens (Pitisuttithum 
et al 2005).
These data suggest that posaconazole has clinical activity 
against fungal infections of the CNS and provides a valuable 
alternative in patients failing existing antifungal agents.
Coccidioidomycosis
Coccidioidomycoosis is a systemic fungal infection caused 
by inhalation of arthroconidia from fungi of the genus 
Coccidioides. Despite the use of amphotericin B, ﬂ  ucon-
azole, and itraconazole, disseminated coccidioidomycosis 
remains difﬁ  cult to treat, and is characterized by frequent 
treatment failures and relapses (Galgiani et al 2000). A non-
comparative, nonrandomized, multicenter study described 
20 patients with chronic pulmonary or nonmeningeal dis-
seminated coccidioidomycosis who received posaconazole 
(400 mg daily) for up to 6 months. In 85% of treated indi-
viduals a satisfactory response, deﬁ  ned as a 50% reduction 
in the Mycoses Study Group score from baseline, could 
be documented (Catanzaro et al 2007). In a case series of 
6 patients with refractory coccidioidomycosis treated with 
posaconazole (800 mg daily) a successful outcome could be 
observed in 5 of 6 subjects after 2–34 months of treatment 
(Anstead et al 2005).
Invasive fusariosis
Fusarium spp. are among the leading fungal pathogens to 
cause invasive mold infections in patients with underlying 
hematopoietic malignancy, particularly in those who have 
undergone HSCT. Conventional amphotericin B-based therapy 
for invasive fusariosis in patients with hematologic malignan-
cies resulted in a 70% failure rate. Amphotericin B or its 
lipid formulation represents the treatment of choice, whereas 
voriconazole is an option for patients refractory or intolerant 
to ﬁ  rst-line therapy. To date one retrospective analysis com-
prising 21 patients with invasive fusariosis, refractory to or 
intolerant of standard antifungals (amphotericin B), evaluated 
posaconazole (800 mg daily in divided doses) as salvage 
therapy. After a duration of administration for up to 12 months, 
an overall response rate of 48% could be observed, suggesting 
that posaconazole is useful as an oral treatment for refractory 
invasive fusariosis (Raad et al 2006b).Therapeutics and Clinical Risk Management 2008:4(4) 754
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Prophylaxis
Antifungal prophylaxis with posaconazole can be 
recommended in HSCT recipients with acute graft versus 
host disease (GVHD) and in patients during induction 
chemotherapy for acute myelogenous leukemia or myelo-
dysplastic syndrome. These recommendations are based 
on two randomized clinical studies. One double-blind trial 
including 600 patients compared posaconazole (600 mg 
daily in divided doses) with ﬂ  uconazole (400 mg daily) 
as prophylaxis against IFI in allogeneic HSCT recipients 
receiving immunosuppressive therapy for treatment of 
GVHD. At 4 months, posaconazole was found to be as 
effective as ﬂ  uconazole in preventing all IFI (incidence: 
5.3% vs 9.0%, p = 0.07) and was superior to ﬂ  uconazole 
in preventing proven or probable invasive aspergillosis 
(2.3% vs 7.0%, p = 0.006). Overall mortality was similar 
in the two groups, but deaths from IFI were lower in the 
posaconazole group (Ullmann et al 2007). The second 
study of 602 subjects compared posaconazole (600 mg 
daily in divided doses) with ﬂ  uconazole (400 mg daily) 
or itraconazole (200 mg twice daily) as prophylaxis for 
IFI in neutropenic patients receiving chemotherapy for 
acute myelogenous leukemia or myelodysplastic syndrome 
(Cornely et al 2007). At 3 months posaconazole was found 
to be superior to the combined ﬂ  uconazole/itraconazole 
group in preventing IFI (2% vs 8%, p  0.001). Rates of 
invasive aspergillosis (1% vs 7%, p  0.001) were also less 
with posaconazole and a signiﬁ  cantly improved survival 
could be observed (p = 0.04). Posaconazole treatment was 
relatively well tolerated in both studies.
Safety and tolerability
During phase I, II, and III clinical trials, posaconazole was 
demonstrated to be safe and well tolerated. In phase I studies 
most adverse events were mild, transient, and nonspeciﬁ  c, 
the most common adverse events including gastrointestinal 
disturbances, headache, dry mouth, somnolence, dizziness, 
fatigue, and constipation (Courtney et al 2003; Ezzet et al 
2005). In a study of 428 patients with refractory invasive 
fungal infections or febrile neutropenia, 109 of whom 
continued treatment for 6 months, 38% reported adverse 
reactions (Raad et al 2006a). However, most of these were 
mild, nausea being the most common (8%), followed by 
vomiting (6%) and abdominal pain (4%). QT interval pro-
longation was observed in 1% of patients and elevation of 
liver enzymes in 2%. Adverse events occurred at similar 
rates in patients who received posaconazole therapy for 6 
months or those treated for 6 months. Long-term therapy 
did not increase the risk of any individual adverse event, and 
no unique adverse event was observed with longer exposure 
to posaconazole (Raad et al 2006a). In two large controlled 
trials, posaconazole seems to have a comparable safety proﬁ  le 
as ﬂ  uconazole or itraconazole. In a study comprising more 
than 600 patients comparing posaconazole vs ﬂ  uconazole or 
itraconazole prophylaxis in patients with neutropenia, seri-
ous adverse events possibly or probably related to treatment 
were reported by 6% in the posaconazole group and in 2% 
in the ﬂ  uconazole or itraconazole group. The most common 
treatment-related adverse events in both groups were gas-
trointestinal tract disturbances (Cornely et al 2007; Ullmann 
et al 2007). Posaconazole therapy is also safe and well toler-
ated in pediatric and elderly patients and treatment-related 
discontinuations are uncommon (Torres et al 2005).
Conclusions and place in therapy
Invasive fungal infections cause substantial morbidity and 
mortality in immunocompromised patients. Since early 
detection and early effective treatment of invasive fungal 
infections can be life saving, the most common approach 
is antifungal prophylaxis and empirical therapy in neu-
tropenic patients with persistent fever. For the future, a 
more reﬁ  ned approach such as pre-emptive therapy – only 
initiated upon identiﬁ  cation of fungal markers in combina-
tion with clinical and radiologic signs – may improve the 
deﬁ  nition of target patients and expose fewer patients to 
potentially toxic and/or expensive treatment. The response 
rate to therapy, in particular for invasive aspergillosis and 
other invasive mold infections, has been poor. With the 
advance of a number of techniques facilitating early diag-
nosis together with the development of new antifungals 
like the echinocandins or extended spectrum azols like 
voriconazole or posaconazole the outcomes for invasive 
fungal infection in immunocompromised patients could 
be improved. In this context, caspofungin has emerged 
as primary therapy of invasive candidiasis (Mora-Duarte 
et al 2002) and neutropenic fever (Walsh et al 2004) and 
voriconacole has largely replaced amphotericin B as ﬁ  rst 
line therapy of invasive aspergillosis (Herbrecht et al 2002). 
Posaconazole is the most broad-spectrum azole antifungal 
to date, with activity against Candida spp., including ﬂ  uco-
nazole-resistant isolates, and Aspergillus spp. Posaconazole 
is likely to be an important new agent in the antifungal 
armamentarium. The primary role for posaconazole will 
be the prophylaxis of IFI in severely immunocompro-
mised patients such as HSCT recipients with acute GVHD 
(Ullmann et al 2007) and neutropenic patients receiving Therapeutics and Clinical Risk Management 2008:4(4) 755
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intensive induction chemotherapy for acute myelogenous 
leukaemia and myelodysplastic syndrome (Cornely et al 
2007). The European Conference on Infections in Leukemia 
(ECIL) guidelines therefore included a provisional AI (ie, 
strongly recommended, based on at least one well-executed, 
randomized trial) recommendation for these indications 
(Maertens 2007). However, the prophylactic use of such a 
broad spectrum agent may lead to the emergence of fungal 
breakthrough infections as it has been suggested that use 
of voriconazole as fungal prophylaxis has led to a possible 
increase of zygomycosis infections in immunocompromised 
patients. Posaconazole is also approved as ﬁ  rst-line treat-
ment of oropharyngeal candidasis including those refractory 
to ﬂ  uconazole or itraconazole in HIV positive patients. There 
is already clinical evidence for its efﬁ  cacy as salvage therapy 
in a number of invasive fungal infections. Posaconazole is 
the only azole to have activity against the zygomycetes, 
including Mucor, Rhizopus, and other species, and has 
shown clinical effectiveness against refractory infections 
caused by these fungi. In addition, there are reasonable 
data showing posaconazole exerts activity against rare, 
difﬁ  cult-to-treat fungi such as Fusarium and Scedosporium 
spp., and has also activity against C. neoformans. Similarly, 
preliminary evidence from noncomparative salvage trials 
suggests its efﬁ  cacy as second-line therapy for invasive 
Aspergillus infection. Nevertheless, many therapeutic areas 
of uncertainty remain. Amphotericin B and caspofungin 
remain the only approved agents for the antifungal man-
agement of febrile neutropenia, but the broad spectrum of 
posaconazole makes it an attractive target for further clinical 
studies. In addition, its role in the treatment of Candida spp. 
remains to be established since no randomized controlled 
studies in yeast infections are available. Finally, the role 
of combination therapies of posaconazole with classes of 
drugs targeting different pathways against ﬁ  lamentous fungi 
(ie, echinocandins) seems to be a promising task and will 
provide a focus for future studies.
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